Eylea drives Regeneron’s 2nd-qtr to beat expectations

5 August 2014

USA-based biotech company Regeneron (Nasdaq: REGN) revealed today that total revenues for the second quarter of 2014 increased by 45% to $665.7 million, topping the average forecast of $648 million among analysts surveyed by Thomson Reuters.

Total revenues include collaboration revenues of $240 million compared to $117 million in the like quarter of 2013, and included payments for French pharma major Sanofi (Euronext: SAN). The company’s shares rose 2.9% to $334.86 by mid morning.

Net product sales were $418 million, compared to $334 million in the second quarter of 2013. Ophthalmic drug Eylea (aflibercept) generated net product sales in the USA of $415 million in the reporting quarter of 2014, compared to $330 million in the second quarter of 2013. Outside the USA, Eylea is sold by German pharma major Bayer (BAYN: DE). Regeneron confirmed its previous forecast for sales of Eylea sales forecasts of $1.7 billion to $1.8 billion for the full year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK